AUTHORS
Bailey E. West, BS, Joseph Kim, PhD2, Li Z Luo, PhD3, Audrey Supreme4, Songlin Wei5, Charlotte Brierley, MD, PhD6, Raajit K. Rampal, MD, PhD7, Amritha Varshini Varshini Hanasoge Hanasoge Somasundara, PhD8, Zanshé Thompson, Ph.D.9, Isha Maloo10, Yuze Du, BSc, MS11, Leslie Cope, PhD12, Alison Moliterno, MD13, Jerry Spivak, MD14, Linda Resar I, MD15
AFFILIATIONS
1 The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
2 The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
3 The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
4 The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
5 The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
6 University of Oxford, Oxford, United Kingdom
7 Memorial Sloan Kettering Institute, New York, New York, United States
8 Memorial Sloan Kettering Institute, New York, New York, United States
9 The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
10 The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
11 The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
12 The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
13 The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
14 The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
15 The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
ABSTRACT
Introduction: MPN are clonal blood disorders with an increased risk of transformation to highly lethal acute myeloid leukemia (AML), yet targetable mechanisms driving progression remain elusive. High Mobility Group A1 (HMGA1) chromatin regulators are up-regulated with MPN progression to AML and required for leukemia transformation (LT) in preclinical models (Li et al Blood 2022). HMGA1 also drives progression in diverse tumors (Chia et al JCI 2023; Luo et al JCI 2025). Although immune escape is a fundamental mechanism of progression in solid tumors, its role in MPN was unknown. We therefore tested the hypotheses that: 1) HMGA1 drives MPN progression by modulating gene networks that promote immune evasion, 2) Targeting HMGA1 networks will trigger an anti-MPN immune attack.
Methods: To dissect mechanisms underlying HMGA1, we performed multiomic approaches (RNA/ChIP/ATAC-seq) followed by gene set enrichment analysis (GSEA) in JAK2V617F AML cell lines. HMGA1 was inactivated via CRISPR or short hairpin RNA. To examine 3D genome architecture, we employed chromosome conformation capture assays. Integrative computational algorithms were used to predict drugs that target HMGA1 networks. The role of Hmga1 in immune escape was tested in mice harboring clones with JAK2V617F and monoallelic Tp53 mutation (JAK2V617F/Tp53fl/+).
Results: Integrative multiomic analyses of JAK2V617FAML cells revealed that HMGA1 represses gene networks associated with interferon γ signaling (NES = -1.75; P<0.001), including major histocompatibility complex (MHC) class I and II genes involved in antigen presentation (AP). Silencing HMGA1 results in up-regulation of MHC genes and proteins, with the greatest induction of MHC-II. To determine how HMGA1 represses AP genes, we examined 3D genome architecture at the MHC II locus. Mechanistically, HMGA1 binds to two super-enhancer regions (XL9, DR/DQ) which govern MHC-II gene expression, and two regions of long-range chromatin interactions mediated by the CCCTC binding factor (CTCF), a genome organizer that orchestrates chromatin looping to activate MHC-II genes (P<10-5). HMGA1 also recruits the repressive histone mark, H3K9me2, to the SE regions and CTCF chromatin interaction regions (denoted CTCF-1 and CTCF-2) to prevent chromatin looping and MHC-II activation. HMGA1-mediated repressive marks (H3K9me2) also prevent binding by CIITA, a master regulator of MHC-II genes. By contrast, HMGA1 silencing “opens” chromatin at the CTCF-1 binding region (ATACseq, P<10-5), thus allowing for CTCF binding and chromatin looping to induce MHC-II AP genes. Using integrative computational algorithms (OptiCon, Cmap), we predicted that the histone deacetylase inhibitor, entinostat, will target HMGA1 gene networks. Strikingly, treatment with entinostat up-regulates AP genes and restores chromatin looping in MPN cells, recapitulating effects of HMGA1 silencing. To test the functional significance of HMGA1 in repressing AP genes, we performed co-culture experiments with T cells and MPN AML cells. HMGA1 silencing in JAK2V617FAML cells results in T cell activation and cytotoxic T cell-mediated killing of AML cells. To examine this pathway in vivo, we compared expansion of JAK2V617F/Tp53fl/+ clones with intact or haploinsufficient Hmga1 and matched, unmutated T cells. Strikingly, the JAK2V617F/Tp53fl/+ clones with Hmga1 haploinsufficiency induce MHC-II compared to those with intact Hmga1. Moreover, recipients transplanted with Hmga1 haploinsufficient clones in the presence of T cells exhibit the lowest mutant allele burdens, consistent with T cell-mediated control of mutant clones. We also treated mice implanted with Jak2V617F/Tp53-/- clones with entinostat, which induces MHC-II and delays LT. To examine the relevance of this pathway in MPN patients, we analyzed bulk RNAseq and scRNAseq from peripheral blood mononuclear cells and CD34+ cells, respectively, and found that HMGA1 expression increases during LT and associates with repression of MHC II genes, particularly in AML with biallelic TP53 mutations.
Conclusions: We discovered a novel epigenetic program whereby HMGA1 disrupts 3D genome architecture at the MHC-II locus to repress MHC-II AP genes and drive immune evasion during MPN progression. HMGA1 depletion or entinostat restores MHC-II expression and activates cytotoxic T cell responses, thus illuminating HMGA1 as a therapeutic target to enhance antitumor immunity and intercept MPN progression.
DISCLOSURES
Linda Resar I, MD: NIH/NCI - Research Funding; American Cancer Society (ACS) - Research Funding; ARDF - Research Funding; MPN Research Foundation - Research Funding; Alex's Lemonade Stand Foundation (ALEX) - Research Funding; WHEN EVERYONE SURVIVES - Research Funding; PharmaEssentia - Research Funding; TEDCO - Research Funding; RALLY Foundation - Research Funding; American Cancer Society (ACS)/St. Baldrick’s Foundation - Research Funding; Department of Defense - Research Funding; Lustgarten - Research Funding